Cancer, Rare Disease Drugs To Be Covered As China Expands Reimbursement

China's national reimbursement drug list will undergo a much anticipated expansion in 2019, and therapies for cancer, pediatric and rare conditions from international firms including Roche and Actellion are likely to receive long-awaited coverage.